KWKimberly P. Woo

Kimberly P. Woo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kimberly P. Woo has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Defining the denominator of inguinal hernia repairs: More than just a number

    by Erika M. Schmidt, Kimberly P. Woo, Aldo Fafaj, Benjamin T. Miller

  • ASO Visual Abstract: The Practices of Pancreatic Neck Margin Testing and Their Outcomes After Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma

    by Kimberly P. Woo, William C. Bennett, Jenny H. Chang, Chase J. Wehrle, Noah X. Tocci, Divya Deverakonda, John McMichael, Robert F. Naples, Kathryn A. Stackhouse, Daniel Joyce, et al.

  • Open Access

    The Practices of Pancreatic Neck Margin Testing and Their Outcomes after Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma

    by Kimberly P. Woo, William C. Bennett, Jenny H. Chang, Chase J. Wehrle, Noah X. Tocci, Divya Deverakonda, John McMichael, Robert F. Naples, Kathryn A. Stackhouse, Daniel Joyce, et al.

    Background: The role of checking the pancreatic neck margin with frozen section (PNM-FS) during pancreatoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDAC) to secure R0 resection and its impact on long-term outcomes remains an area of debate. Patients and Methods: Patients with PD for PDAC between 2018 and 2023 were included. The primary outcome was pancreatic neck recurrence-free survival (PN-RFS). Secondary outcomes were locoregional recurrence-free survival (LR-RFS), distant recurrence-free survival (D-RFS), and overall survival (OS). Results: There were 403 patients who met inclusion criteria. PNM-FS was checked in 361 patients (89.6.2%) and returned negative at first attempt in 285 (78.9%). A total of 76 patients had positive PNM-FS; 71 were revised and clearance achieved on repeat sampling in 49 (69.0%). Median PN-RFS in patients with PNM-FS cleared with revision was significantly shorter compared with those with negative PNM-FS at first attempt (16.9 versus 23.1 months; p = 0.048) but was not different from patients with PNM-FS not cleared (16.9 versus 16.0 months; p = 0.961). LR-RFS and D-RFS were not different between the groups. OS was marginally longer in patients with negative PNM-FS at first attempt (23.9 versus 19.4 versus 16.0 months; p = 0.049). Six patients underwent completion total pancreatectomy (TP) for margin clearance, four developed distant recurrence, one locoregional recurrence and two died without disease at 1 and 11 months postoperatively. Conclusions: PNM-FS is only a prognostic marker. Pursuing PNM-FS clearance does not improve PN-RFS, LR-RFS, D-RFS, or OS. Furthermore, pursuing a completion TP may be associated with shorter OS either from disease progression or surgical morbidity.

  • Open Access

    Venous thromboembolism after ventral hernia repair with transversus abdominis release

    by Kimberly P. Woo, Sergio Mazzola Poli de Figueiredo, Sarah L. Larson, Joseph D. Quick, Sara M. Maskal, Daphne Remulla, William C. Bennett, Kimberly S. Miles, Chao Tu, Lucas R. Beffa, et al.

    Introduction: Venous thromboembolism (VTE) events, such as pulmonary embolism (PE) and deep venous thrombosis (DVT), are a significant source of morbidity and mortality after major abdominal wall reconstruction. We aim to describe the incidence of VTE events in patients undergoing ventral hernia repair (VHR) with transversus abdominis release (TAR) at our institution. Methods: The Abdominal Core Health Quality Collaborative registry was queried for patients, 18 years and older, who underwent VHR with TAR at our institution between August 2014 and December 2023. Patient characteristics and operative details were obtained from the registry. Patient electronic medical records were reviewed for outcomes. The primary study outcome was the incidence of VTE, including PE and DVT, within 8 weeks postoperatively. Secondary outcomes included time to VTE, VTE chemoprophylaxis protocol used, VTE management, and complications. Results: Of the 3555 patients who underwent abdominal wall reconstruction and met inclusion criteria, 100 patients experienced (2.8%) VTE events; 58 patients had a PE and 42 had DVTs. The median time to a VTE event was 7 (IQR 4–14) days after surgery, and 27% of VTE events occurred after hospital discharge. Of the patients who experienced a VTE event, 77 received preoperative chemoprophylaxis and 66 patients received postoperative chemoprophylaxis beginning on the day of surgery. In 19 patients, chemoprophylaxis was interrupted prior to development of VTE. Most patients (n = 88) were managed with systemic anticoagulation, and 18.1% had a bleeding complication related to anticoagulation treatment. Conclusion: Patients undergoing major abdominal wall reconstruction are at high risk for venous thromboembolism events, even after hospital discharge. Further studies are needed to determine risk factors associated with VTE in this specific patient population to optimize perioperative anticoagulation strategies.


  • Integrating Sustainability Into Graduate Medical Education for Surgical Trainees

    by Katie Foug, Armaan Patel, Jenny H. Chang, Kimberly Woo, Abby Gross, Sofya Asfaw, Benjamin Miller


  • Characterizing patterns of opioid prescribing after outpatient ventral hernia repair with mesh

    by Kimberly P. Woo, Xinyan Zheng, Amitabh P. Goel, Rana M. Higgins, Anthony A. Iacco, Todd S. Harris, Jeremy A. Warren, Michael Reinhorn, Clayton C. Petro

    Purpose Despite efforts to minimize opioid prescribing, outpatient ventral hernia repair (VHR) with mesh remains notoriously painful, often requiring postoperative opioid analgesia. Here, we aim to characterize patterns of opioid prescribing for the heterogenous group of patients and procedures that comprise mesh-based, outpatient VHR. Methods The Abdominal Core Health Quality Collaborative registry was queried for patients undergoing VHR with mesh who were discharged the same or next day between January 2019 to October 2023. Procedures were broadly classified by approach and mesh location: open, minimally-invasive with intraperitoneal mesh (MIP), and minimally-invasive with retromuscular or preperitoneal mesh (MRPP). Surgeon-reported opioid prescription quantity and patient-reported 30-day consumption data were reviewed. Results Of 2,795 patients who met inclusion criteria (46.1% open, 22.7% MIP, 31.2% MRPP), approximately 80% of patients consumed ≤ 10 tablets of opioid pain medication (open 87.7%, MIP 78.4%, MRPP 84.2%). For patients who were prescribed ≤ 10 tablets, the median number of unconsumed tablets was 5 (IQR 0–8). For patients who were prescribed > 10 tablets, the median number of unconsumed tablets was 10 or more (open 10 [IQR 2–16], MIP 10 [IQR 2–18], MRPP 12 [IQR 5–16]). The number of tablets consumed was positively correlated with the number of tablets prescribed (Kendall's rank correlation = 0.232, p < 0.001). Conclusion Regardless of technique, for outpatient VHR with mesh, the fewer opioid tablets prescribed, the fewer tablets patients consumed. Decreasing the prescription quantity to ≤ 10 tablets, coupled with preoperative patient education, may help minimize excess opioid prescribing while still achieving adequate pain control.


  • Open Access

    The role of chemotherapy in the management of pancreatic acinar cell carcinoma

    by Kimberly P. Woo, Chase J. Wehrle, Daphne Remulla, Jenny H. Chang, Robert Naples, Daniel Joyce, Robert Simon, Toms Augustin, R. Matthew Walsh, Samer A. Naffouje

    Introduction: Pancreatic acinar cell carcinoma (pACC) is a rare malignancy with unique clinical and molecular features. The role of chemotherapy in pACC management is not well established.Methods: The National Cancer Database (NCDB) for pACC was used. Cox regression was used in resected pACC patients to identify significant overall survival (OS) predictors. Patients were then divided based on these risk factors into propensity‐matched group of surgery versus surgery + chemotherapy and Kaplan–Meier analysis was performed with log‐rank tests to compare OS.Results: The NCDB 2004–2020 included 1592 pACC patients, 1553 were selected. Median age was 66 and 1090 (70.2%) were males. 622 (40.1%) received chemotherapy only, 257 (16.5%) had surgery only, and 365 (23.5%) had both. 189 Patients who received surgery were only matched to peers who had surgery + chemotherapy. The median OS for surgery only was 57.8 ± 6.0 versus 54.2 ± 9.9 months for surgery + chemotherapy (p = 0.836). Cox regression identified nodal and margin status as independent predictors of OS. Therefore, subgroups of patients with node‐negative, node‐positive, margin‐negative, and margin‐positive resections were similarly matched 1:1 for the receipt of surgery only versus surgery + chemotherapy. Only patients with node‐positive disease had a significant OS benefit with the addition of chemotherapy (44.2 ± 7.3 vs. 27.5 ± 10.5 months; p = 0.036).Conclusion: Our analysis suggests that surgical resection remains the cornerstone of therapy for pACC. Node status and margin status are the primary prognosticators. The addition of chemotherapy provides an OS benefit only in node‐positive disease.


  • Open Access

    Comparing oncologic and surgical outcomes of robotic and laparoscopic distal pancreatectomy: a propensity-matched analysis

    by Jenny H. Chang, Chase Wehrle, Kimberly Woo, Robert Naples, Kathryn A. Stackhouse, Fadi Dahdaleh, Daniel Joyce, Robert Simon, Toms Augustin, R. Matthew Walsh, et al.

    Background: The frequency of minimally invasive distal pancreatectomy is gradually exceeding that of the open approach. Our study aims to compare short-term outcomes of robotic (RDP) and laparoscopic (LDP) distal pancreatectomies for pancreatic ductal adenocarcinoma (PDAC) using a national database. Methods: The National Cancer Database was utilized to identify patients with PDAC who underwent distal pancreatectomy from 2010–2020. Short-term technical and oncologic outcomes such as margin status and nodal harvest were included. Propensity-score matching (PSM) was performed comparing LDP and RDP cohorts. Multivariate logistic-regression models were then used to assess the impact of institutional volume on the MIDP surgical and technical oncologic outcomes. Results: 1537 patients underwent MIDP with curative intent. Most cases were laparoscopic (74.4%, n = 1144), with a gradual increase in robotic utilization, from 8.7% in 2010 to 32.0% of MIDP cases ten years later. For PSM, 698 LDP patients were matched with 349 RDP. The odds of conversion to an open case were 58% less in RDP (12.6%) compared to LDP (25.5%) with no statistically significant difference in technical oncologic results. There was no difference in length of stay (OR = 1.0[0.7–1.4]), 30-day mortality (OR = 0.5[0.2–2.0]) or 90-day mortality (OR = 1.1[0.5–2.4]) between RDP and LDP, although there was a higher 30-day readmission rate with RDP (OR = 1.71[1.1–2.7]). There were statistically significant differences in technical oncologic outcomes (nodal harvest, margin status, initiation of adjuvant therapy) based on MIDP volume quartiles. Conclusion: Laparoscopic and robotic distal pancreatectomy have similar peri- and post-operative surgical and oncologic outcomes, with a higher rate of conversion to open in the laparoscopic cohort.


  • Open Access

    Neoadjuvant therapy reduces node positivity but does not confer survival benefit versus up‐front resection for resectable intrahepatic cholangiocarcinoma: A propensity‐matched analysis

    by Chase J. Wehrle, Jenny Chang, Kimberly Woo, Abby Gross, Robert Naples, Fadi Dahdaleh, Kathryn Stackhouse, Jaekeun Kim, Toms Augustin, Robert Simon, et al.

    Background: Neoadjuvant systemic therapy (NAST) is a treatment option for intrahepatic cholangiocarcinoma (iCCA), though its impact on short‐term oncologic outcomes and long‐term survival remains relatively unknown.Methods: The National Cancer Database (NCDB) between 2004 and 2019 was queried for patients with reportedly resectable (Stage I−IIIB) iCCA who received curative‐intent resection with lymphadenectomy. Propensity matching was performed between groups based on the use of NAST and groups were compared for overall survival (OS) and oncologic outcomes, including nodal harvest, rate of node positivity, rate of positive margins, and administration of adjuvant therapy.Results: Two thousand and five hundred ninety‐six patients met inclusion criteria; 364 (14%) received NAST versus 1763 (68%) up‐front resection. After matching, 332 pairs of patients were matched between NAST and no NAST. Patients receiving NAST had a greater nodal harvest (OR = 1.26 [1.09−1.88]; p < 0.001) and a lower rate of node positivity (OR = 0.67 [0.49−0.63]; p < 0.001). Patients without NAST were more likely to complete adjuvant systemic therapy (OR = 0.45 [0.33−0.62]; p < 0.001). However, patients receiving NAST had no OS benefit after resection compared to those who did not receive NAST (median OS 48.3 ± 5.3 vs. 38.8 ± 3.7 months; p = 0.160). Node‐positive disease (OR = 2.10 [1.78−2.45]; p < 0.001) conferred the greatest risk for reduced OS followed by positive‐margin resection (OR = 1.42 [1.21−1.47]; p < 0.001) and increasing T‐stage (OR = 1.34 [1.21−1.47]; p < 0.001).Conclusion: NAST for iCCA was associated with improved quality of oncologic resection but did not confer an OS benefit versus up‐front resection.


  • Open Access

    Does reusable mean green? Comparison of the environmental impact of reusable operating room bed covers and lift sheets versus single-use

    by Jenny H. Chang, Kimberly P. Woo, Nathalia Silva de Souza Lima Cano, Melissa M. Bilec, Maya Camhi, Alexandra I. Melnyk, Abby Gross, R. Matthew Walsh, Sofya H. Asfaw, Ilyssa O. Gordon, et al.